We respond to NICE decision to approve Enhertu for people with HER2-low metastatic breast cancer

“Today, we can finally say we did it. After more than two years of relentless campaigning, Enhertu has been recommended by NICE for use on the NHS in England for people with HER2-low metastatic breast cancer.

“This is a momentous day for thousands of people who will now have access to a drug that could give them precious extra time with loved ones. More ordinary days that become extraordinary because they were there.

“This milestone victory belongs to every person who refused to accept that access to a life-extending treatment was out of reach. For people in England, the wait for Enhertu is finally over. We must now also see Wales and Northern Ireland make Enhertu available for use on the NHS for those who need more time to live.

“This victory belongs to the women with metastatic breast cancer who continued campaigning when they could have been spending their precious time with their loved ones. It belongs to everyone who signed our petitions, contacted their MPs, shared our campaign and kept the pressure on, including METUPUK and Make 2nds Count who campaigned alongside us.

“Together, we never gave up. And today, persistence paid off. But we can’t celebrate this momentous decision without remembering the devastating cost of this delay.

“Since 2024 when it was first rejected for use, thousands of people have missed out on access to Enhertu and tragically many have died. We remember with deep gratitude the women who stood alongside us and fought for this very moment. Women who were mums, daughters, sisters like Hannah, Jeannie and Tracy. We owe it to them to make sure this never happens again.

“We are calling on the government, NICE, NHS England and the pharmaceutical industry to work together to fix this broken system, so that people with incurable metastatic breast cancer are not forced to spend precious months and years campaigning for treatments that could give them more time.

“We are determined to keep championing for every person with metastatic breast cancer to get the best possible treatment, as quickly as possible, wherever they live.”